Articles

Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey
Centre Régional de Cancérologie Henry Kaplan CHRU de Tours, Hôpital Bretonneau, Tours, France
Haematology Department, Western General Hospital, Edinburgh, UK
Covance for Janssen-Cilag, Issy-les-Moulineaux, France
Janssen-Cilag, Tilburg, The Netherlands
Janssen-Cilag, Issy-les-Moulineaux, France
Biostatistics Department, PAREXEL International, Paris, France
Janssen-Cilag, Neuss, Germany
CHRU de Lille Hôpital Claude Huriez, Service des Maladies du Sang, Lille, France
Vol. 98 No. 8 (2013): August, 2013 https://doi.org/10.3324/haematol.2013.084376